(MGRO) MustGrow Biologics - Ratings and Ratios
Exchange: V • Country: Canada • Currency: CAD • Type: Common Stock •
MGRO: Biopesticides, Biofertilizers, Soil Amendments, Biocontrols
MustGrow Biologics Corp. (V:MGRO) is an agricultural biotechnology company specializing in the development and commercialization of natural biological technologies derived from mustard seeds. The companys Biocontrol technology platform addresses soil-borne diseases and pests across various crops, including fruits and vegetables, while also targeting organic agriculture and home garden markets where glyphosate is banned. Additionally, the platform is used to suppress sprouting and treat diseases in storage and food preservation. The companys product portfolio includes TerraMG, a mustard-derived soil biopesticide, and TerraSante, an organic soil amendment and biofertility technology under development. Established in 2014 and headquartered in Saskatoon, Canada, MustGrow Biologics Corp. was formerly known as Duport Capital Ltd. before changing its name in March 2018.
Over the next three months, MustGrow Biologics Corp. (V:MGRO) is expected to face a challenging environment based on current technical and fundamental analysis. Technically, the stock is in a downtrend, with the last price of 1.15 sitting below the SMA20 (1.32) and SMA50 (1.39), indicating bearish momentum. The SMA200 at 1.22 further suggests that the stock is trading below its long-term average, reinforcing the downtrend. The ATR of 0.10 signals low volatility, which may limit significant price movements in either direction. On the fundamental side, the companys high P/B ratio of 18.70 and P/S ratio of 12.62 indicate a premium valuation relative to its book value and sales, which could pose a challenge for investors seeking value. The negative RoE of -7.27 highlights ongoing profitability challenges, which may weigh on investor sentiment. However, the companys focus on R&D and product development could position it for potential growth if it secures new partnerships or regulatory approvals. Overall, the stock is likely to remain under pressure in the near term, with limited upside potential unless driven by positive catalysts.
Additional Sources for MGRO Stock
MGRO Stock Overview
Market Cap in USD | 35m |
Sector | Basic Materials |
Industry | Agricultural Inputs |
GiC Sub-Industry | Fertilizers & Agricultural Chemicals |
IPO / Inception |
MGRO Stock Ratings
Growth Rating | 40.8 |
Fundamental | -30.0 |
Dividend Rating | 0.0 |
Rel. Strength | 14.2 |
Analysts | - |
Fair Price Momentum | 1.01 CAD |
Fair Price DCF | - |
MGRO Dividends
No Dividends PaidMGRO Growth Ratios
Growth Correlation 3m | -91.1% |
Growth Correlation 12m | 54.7% |
Growth Correlation 5y | -5.8% |
CAGR 5y | 28.70% |
CAGR/Max DD 5y | 0.33 |
Sharpe Ratio 12m | -0.05 |
Alpha | 4.33 |
Beta | 0.892 |
Volatility | 100.50% |
Current Volume | 13.5k |
Average Volume 20d | 6.9k |
As of April 19, 2025, the stock is trading at CAD 1.13 with a total of 13,500 shares traded.
Over the past week, the price has changed by +4.63%, over one month by -6.61%, over three months by -22.07% and over the past year by +5.61%.
Probably not. Based on ValueRay Fundamental Analyses, MustGrow Biologics (V:MGRO) is currently (April 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -29.96 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MGRO as of April 2025 is 1.01. This means that MGRO is currently overvalued and has a potential downside of -10.62%.
MustGrow Biologics has no consensus analysts rating.
According to ValueRays Forecast Model, MGRO MustGrow Biologics will be worth about 1.1 in April 2026. The stock is currently trading at 1.13. This means that the stock has a potential downside of -0.88%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 1.1 | -0.9% |